Gossamer Bio director granted 115,000 stock options

Gossamer Bio, Inc. director Nathan Steven D received a grant of stock options for 115,000 shares of common stock at an exercise price of $0.1780 per share.

Rhea-AI Filing Summary

Gossamer Bio, Inc. director Nathan Steven D received a grant of stock options for 115,000 shares of common stock at an exercise price of $0.1780 per share. The options expire on June 3, 2036 and vest in full on the earlier of the first anniversary of the grant or the next annual stockholder meeting, subject to continued board service.

Insider Trade Summary

Grant/Award: 115,000 shares

Grant/Award 1 txn

Insider Nathan Steven D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	115,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 115,000 contracts (Direct)

Footnotes (2)

1. F1. Award made pursuant to Non-Employee Director Compensation Program.
2. F2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Key Figures

Option grant size: 115,000 options Exercise price: $0.1780 per share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 115,000 options Stock Option (Right to Buy) granted to director

Exercise price $0.1780 per share Conversion or exercise price for the options

Expiration date June 3, 2036 Option expiration for granted stock options

Underlying shares 115,000 shares Common stock underlying the stock options

Holdings after grant 115,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), Non-Employee Director Compensation Program, vesting, annual meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Non-Employee Director Compensation Program financial

"Award made pursuant to Non-Employee Director Compensation Program."

vesting financial

"becomes fully vested and exercisable on the first to occur of (a) the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"or (b) the next occurring annual meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GOSS report for Nathan Steven D?

Gossamer Bio reported that director Nathan Steven D received a grant of 115,000 stock options. These options give him the right to buy common shares at a fixed exercise price as part of his non-employee director compensation.

What are the key terms of Nathan Steven D’s GOSS stock option grant?

The grant covers 115,000 options with an exercise price of $0.1780 per share, expiring on June 3, 2036. All options relate to Gossamer Bio common stock and were issued under the non-employee director compensation program.

When do the newly granted GOSS stock options vest for Nathan Steven D?

The entire 115,000-share option grant becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving on Gossamer Bio’s board until that vesting date.

Is Nathan Steven D’s GOSS option grant an open-market purchase or a compensation award?

The transaction is a compensation award, not an open-market purchase. It is described as a grant of stock options made pursuant to Gossamer Bio’s Non-Employee Director Compensation Program for board service.

How many GOSS derivative securities does Nathan Steven D hold after this Form 4?

After the reported transaction, Nathan Steven D holds 115,000 derivative securities in the form of stock options. These options each relate to one share of Gossamer Bio common stock, according to the filing details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nathan Steven D

(Last) (First) (Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.178	06/04/2026		A		115,000(1)		(2)	06/03/2036	Common Stock	115,000	$0	115,000	D

Explanation of Responses:

1. Award made pursuant to Non-Employee Director Compensation Program.

2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Christian Waage, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)